NEW YORK (GenomeWeb News) – Response Genetics today announced it has acquired the "key assets" of Pathwork Diagnostics, including its US Food and Drug Administration-cleared and Medicare-reimbursed test for diagnosing metastatic, poorly differentiated, and undifferentiated cancer.

In a document filed with the US Securities and Exchange Commission, Response said it will pay up to $1.35 million for the Pathwork assets, including a $200,000 cash payment and issuance of 500,000 shares of Response's stock with a lock-up period through June 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.